Research Analysts Issue Forecasts for KPTI Q1 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Investment analysts at HC Wainwright increased their Q1 2026 EPS estimates for shares of Karyopharm Therapeutics in a report issued on Wednesday, March 25th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($1.05) per share for the quarter, up from their previous forecast of ($1.17). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.69) EPS and FY2026 earnings at ($3.17) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The company had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million.

A number of other analysts also recently commented on the company. Robert W. Baird dropped their price objective on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research note on Thursday, February 5th. They set an “overweight” rating for the company. Finally, The Goldman Sachs Group set a $12.00 price objective on Karyopharm Therapeutics in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $14.86.

Karyopharm Therapeutics Stock Down 1.6%

NASDAQ:KPTI opened at $5.48 on Friday. The company has a market cap of $100.50 million, a P/E ratio of -0.33 and a beta of 0.13. The firm’s 50 day moving average is $7.72 and its two-hundred day moving average is $6.82. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $10.99.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics in the second quarter valued at about $45,000. XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth about $56,000. Corient Private Wealth LLC purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth about $74,000. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth about $95,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at about $135,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics News Summary

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Karyopharm announced a new equity financing that should bolster liquidity and extend runway, easing short‑term funding risk. Karyopharm Strengthens Liquidity With New Equity Financing
• Positive Sentiment: HC Wainwright raised its EPS forecasts across multiple quarters and reiterated a “Buy” rating with an $8 price target — the analyst upgrades signal improved near‑term expectations for operating performance. MarketBeat HC Wainwright Coverage
• Neutral Sentiment: Zacks noted that KPTI shares jumped ~6.9% on above‑average volume recently but also warned that the recent trend in earnings‑estimate revisions doesn’t strongly support further upside. Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
• Negative Sentiment: A Seeking Alpha analysis contextualized mixed Phase 3 SENTRY results for selinexor (met spleen endpoint but missed symptom endpoint), highlighted an immature overall‑survival signal, and emphasized a tight cash runway — even after a $30M private placement — leaving existential funding risk if additional financing is delayed or unfavorable. Karyopharm: Putting The Phase 3 Trial In Context
• Negative Sentiment: Robert W. Baird published a bearish/pessimistic forecast for KPTI’s stock price, adding downside analyst pressure and signaling investor caution. Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.